Company

Management

  • Maria Palasis, Ph.D.

    President and Chief Executive Officer

    Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO of 480 Biomedical and CEO and Chief Technology Officer of Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

    Maria Palasis is an industry veteran in merging material science and drug-delivery innovation to create best-in-class therapies for patients. She brings nearly 25 years of healthcare industry experience to Lyra. A repeat entrepreneur, her transformative leadership as CEO of 480 Biomedical and CEO and Chief Technology Officer of Arsenal Medical resulted in >$160 million of external and non-dilutive funding and the advancement of multiple programs into the clinic. Earlier in her career, she managed a portfolio of external biotech and medical device investments at Boston Scientific and led the development of several combination therapies. She is an inventor on more than 120 issued and pending patents. Maria received her B.S. and Ph.D. in Chemical Engineering from the University of Cincinnati, and she held a postdoctoral fellowship in molecular biology at the University of Cincinnati School of Medicine.

  • Corinne Noyes

    Senior Vice President of Commercial Strategy & Market Development

    Corinne Noyes has more than 20 years of commercial experience working with pharmaceutical companies from seed-stage ventures to multi-national corporations. An expert at maximizing the commercial potential of therapeutic assets, she brings to the company extensive experience across varied technologies and therapeutic areas. Prior to Lyra she built a thriving consultancy, where she advised leading start-up biotech companies and contributed to successful M&A activity exceeding over $2.5B in deal value and developed commercial strategies that collectively raised over $300M in IPOs. Previously, Corinne held commercial leadership positions at Biogen in global new product planning and marketing. She began her life sciences career in the New York pharmaceutical practice of Deloitte Management Consulting. Corinne holds a B.A. and B.B.A. from St. Mary’s College of Notre Dame and an M.B.A. from the University of Chicago.

    Corinne Noyes has more than 20 years of commercial experience working with pharmaceutical companies from seed-stage ventures to multi-national corporations. An expert at maximizing the commercial potential of therapeutic assets, she brings to the company extensive experience across varied technologies and therapeutic areas. Prior to Lyra she built a thriving consultancy, where she advised leading start-up biotech companies and contributed to successful M&A activity exceeding over $2.5B in deal value and developed commercial strategies that collectively raised over $300M in IPOs. Previously, Corinne held commercial leadership positions at Biogen in global new product planning and marketing. She began her life sciences career in the New York pharmaceutical practice of Deloitte Management Consulting. Corinne holds a B.A. and B.B.A. from St. Mary’s College of Notre Dame and an M.B.A. from the University of Chicago.

  • Robert Solomon

    Vice President of Finance

    Robert Solomon has a 20-year track record of guiding entrepreneurial life sciences companies through the financial and accounting complexities unique to the industry. Prior to Lyra Therapeutics, he was Vice President of Finance for GI Dynamics, Inc. In this role, Robert was responsible for accounting, SEC and Australian Stock Exchange reporting, financial planning, tax compliance, risk management and treasury. Previously, Robert held senior finance roles at Ironwood Pharmaceuticals, Targanta Therapeutics, Therion Biologics and Aspect Medical Systems. Robert holds an M.B.A. from the Stern School of Business at New York University and a B.S. from Cornell University.

    Robert Solomon has a 20-year track record of guiding entrepreneurial life sciences companies through the financial and accounting complexities unique to the industry. Prior to Lyra Therapeutics, he was Vice President of Finance for GI Dynamics, Inc. In this role, Robert was responsible for accounting, SEC and Australian Stock Exchange reporting, financial planning, tax compliance, risk management and treasury. Previously, Robert held senior finance roles at Ironwood Pharmaceuticals, Targanta Therapeutics, Therion Biologics and Aspect Medical Systems. Robert holds an M.B.A. from the Stern School of Business at New York University and a B.S. from Cornell University.

  • Danny Concagh

    Senior Director, Chemistry and Pilot Manufacturing

    Danny Concagh has extensive expertise in polymer science and formulation that he has cultivated over 20 years in the pharmaceutical and biotech industries. In his role at Lyra Therapeutics, he led the design of Lyra’s transmucosal therapeutic matrix and oversees Lyra’s pilot manufacturing facility. Prior to Lyra, he held positions at Copley Pharmaceuticals, GelTex Pharmaceuticals and Genzyme. At GelTex Pharmaceuticals (acquired by Genzyme in 2000 for $1.1 billion), he was instrumental in the discovery and development of several oral non-systemic polymeric drugs. Danny is an inventor on numerous issued or pending patents and holds an M.Sc. in Organic Chemistry from the National University of Ireland, Galway.

    Danny Concagh has extensive expertise in polymer science and formulation that he has cultivated over 20 years in the pharmaceutical and biotech industries. In his role at Lyra Therapeutics, he led the design of Lyra’s transmucosal therapeutic matrix and oversees Lyra’s pilot manufacturing facility. Prior to Lyra, he held positions at Copley Pharmaceuticals, GelTex Pharmaceuticals and Genzyme. At GelTex Pharmaceuticals (acquired by Genzyme in 2000 for $1.1 billion), he was instrumental in the discovery and development of several oral non-systemic polymeric drugs. Danny is an inventor on numerous issued or pending patents and holds an M.Sc. in Organic Chemistry from the National University of Ireland, Galway.